Compare EMPD & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EMPD | ACET |
|---|---|---|
| Founded | 2020 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.5M | 83.3M |
| IPO Year | 2021 | 2017 |
| Metric | EMPD | ACET |
|---|---|---|
| Price | $2.99 | $9.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $48.33 |
| AVG Volume (30 Days) | ★ 458.5K | 74.1K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.47 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $974,977.00 | N/A |
| Revenue This Year | $23.49 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.48 | $0.46 |
| 52 Week High | $8.17 | $9.97 |
| Indicator | EMPD | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 48.38 | 58.39 |
| Support Level | $2.64 | $7.45 |
| Resistance Level | $3.15 | $9.59 |
| Average True Range (ATR) | 0.25 | 0.52 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 32.09 | 66.67 |
Empery Digital Inc is an all-electric, off-road powersports vehicle company developing and building electric two and four-wheel motorcycles and utility terrain vehicles, also known as side-by-sides, along with a complete line of upgrades and accessories. The company's products include motorcycle and UTV products that are all-electric and designed for off-road use.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).